Design of clinically useful iron(III)-selective chelators.
about
Retinal iron homeostasis in health and diseaseIron homeostasis and toxicity in retinal degenerationIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesSynthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: Developing a structure–activity relationshipComplex Formation of ICL670 and Related Ligands with FeIIIand FeIIAntiproliferative effect on HepaRG cell cultures of new calix[4]arenes. Part II.Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89Lysosomal iron mobilization and induction of the mitochondrial permeability transition in acetaminophen-induced toxicity to mouse hepatocytes.Advances in iron chelation: an update.Design of iron chelators with therapeutic application.Inhibition of cellulase-catalyzed lignocellulosic hydrolysis by iron and oxidative metal ions and complexes.New Synthetic Approach for the Incorporation of 3,2-Hydroxypyridinone (HOPO) Ligands: Synthesis of Structurally Diverse Poly HOPO Chelators.The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.Iron accumulation and neurotoxicity in cortical cultures treated with holotransferrinChelators in the treatment of iron accumulation in Parkinson's disease.New methodology for the preparation of 3-hydroxy-2-pyridinone (3,2-HOPO) chelators - Reaction of amines with a novel electrophilic 3,2-HOPO precursorNew methodology for the preparation of 3-hydroxy-2-pyridinone (3,2-HOPO) chelators and extractants. Part 2. Reactions of alcohols, phenols, and thiols with an electrophilic 3,2-HOPO reagent()Therapeutic potential of iron chelators in diseases associated with iron mismanagement.Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury.Synthetic and natural iron chelators: therapeutic potential and clinical useTranslocation of iron from lysosomes to mitochondria during ischemia predisposes to injury after reperfusion in rat hepatocytes.Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68.Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development.The potential application of iron chelators for the treatment of neurodegenerative diseases.Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice.A review of metal-catalyzed molecular damage: protection by melatonin.Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators.A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry.Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probesAntiproliferative effect on HepaRG cell cultures of new calix[4]arenes.Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications.Long-term storage of lyophilized liposomal formulations.Translocation of iron from lysosomes to mitochondria during acetaminophen-induced hepatocellular injury: Protection by starch-desferal and minocycline.Iron Deficiency Impairs Developing Hippocampal Neuron Gene Expression, Energy Metabolism, and Dendrite Complexity.3,2-Hydroxypyridinone (3,2-HOPO) vinyl sulfonamide and acrylamide linkers: Aza-Michael addition reactions and the preparation of poly-HOPO chelators.Efficient synthesis of 5-amido-3-hydroxy-4-pyrones as inhibitors of matrix metalloproteinases.Synthesis of polymers containing 3-hydroxypyridin-4-one bidentate ligands for treatment of iron overload.Activation of caspase pathways during iron chelator-mediated apoptosis.Multicellular aggregation of maltol-modified cells triggered by Fe(3+) ions.
P2860
Q21131069-72014B19-9FFE-4D65-BBE2-8349482205BCQ28252419-2AA8B791-B495-438E-880A-F378533D1008Q28388335-0CB07867-474F-4718-8C71-ADA7A4F0DC09Q29012564-179F66E4-A086-4ABD-AF05-2A101CDA2148Q29308239-27BC1729-2296-40B0-932D-B2D3F94C36D0Q33603341-9986D630-DA94-467E-A483-16B1E2971053Q33757834-D1332EFB-B557-4834-BC35-311A7508D5ECQ34071991-E7B8C1DD-BF31-4C3B-952C-3894B9133135Q34174307-8B715982-1B7F-4ED2-A903-B9C8F07F2BEBQ34258805-884CAF6E-EBBA-4185-BBB5-CB3B0BD28C64Q34334762-2E8E156E-428C-4B8E-AFF5-304CCD6C8533Q35060340-27E0B173-FFB7-4EDF-9FFA-0706FF5ED07FQ35545150-14E57213-36FF-4DE2-848F-B1702656C818Q35937824-0DDC2471-B001-4E73-916B-280AF553EEFFQ36056203-6C630911-4BC3-402A-83A1-31D63ED587B1Q36364649-6EFF5EF8-DDCF-4643-90D7-847EA30419CCQ36399670-C5F7AD6C-5B0A-4CB0-B632-2A2DE0C01FFCQ36461028-7172180D-4C49-4E8A-BC71-58A2245925D7Q36957543-785744E8-72FF-4DDA-BC3B-3F82F10763A9Q36964130-7DE3D57B-B3F7-4DDA-BB52-13746B33CC84Q37290073-2C8A2BEA-4D55-445B-9685-EA80BD38AC8CQ37599003-10718FF6-65BC-423D-BCEE-4EF0676AA884Q37631557-2CD0B44B-3021-426F-9D21-73C8B1237D43Q37718007-C909A611-9CD6-4711-8F91-DEA0AD1B98FFQ37846107-888F5E39-D55D-4D48-9DC0-84F3381E4330Q37928941-926A30D7-7E39-4DC0-BF9F-1D3737601A3AQ38195865-19877734-8D79-49ED-A2F1-E4CA304BA759Q38898546-5130B664-7974-4494-A9AE-1AA147385C9BQ39198457-B860A42B-0AD0-4457-B7B7-0B5FA9CA3050Q39738784-F53F5A1C-EE55-4241-A977-A8153D950AC4Q39780371-706DB13E-AEFB-47C6-B94B-84667AFD9444Q40099320-3DD79A2A-D107-40CB-9574-F0CD53347DA4Q40970825-543752E4-8633-46AC-8B94-5584ABCB72AAQ41247629-717A0D21-BF5E-45F2-ACA1-8373296B709FQ41683781-854FD5BC-D8B2-4B5B-B5D1-D5B727B87F41Q41950065-7D953D8E-A0B9-4955-88B9-8A1E80F01DF1Q42430174-E0C0D004-52C2-434D-8ECC-0163DE761805Q43199005-6C328E91-FAA1-4E88-A83D-687668DB2630Q43974203-1CD174D0-C55E-47EA-A57D-334D7F0BF9C9Q44100369-9EBDA94E-6507-4610-919E-2243222D0C61
P2860
Design of clinically useful iron(III)-selective chelators.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Design of clinically useful iron
@nl
Design of clinically useful iron(III)-selective chelators.
@ast
Design of clinically useful iron(III)-selective chelators.
@en
type
label
Design of clinically useful iron
@nl
Design of clinically useful iron(III)-selective chelators.
@ast
Design of clinically useful iron(III)-selective chelators.
@en
prefLabel
Design of clinically useful iron
@nl
Design of clinically useful iron(III)-selective chelators.
@ast
Design of clinically useful iron(III)-selective chelators.
@en
P2860
P356
P1476
Design of clinically useful iron(III)-selective chelators.
@en
P2093
Robert C Hider
P2860
P356
10.1002/MED.1027
P577
2002-01-01T00:00:00Z